Single-dose, placebo-controlled, phase I study of oral dolasetron

Pharmacotherapy

Volumn 16, Issue 2 I, 1996, Pages 245-252

  Dixon, Russell M ^a   Cramer, Michael ^b   Shah, Ajit K ^b   Whitmore, James ^b   Benedict, Claude R ^c   Hahne, William F ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b SANOFI   (France)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOLASETRON MESILATE; HYDRODOLASETRON; PLACEBO; SEROTONIN 3 ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; APPETITE DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; VERTIGO;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIEMETICS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; HUMANS; INDOLES; MALE; MIDDLE AGED; NAUSEA; QUINOLIZINES; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0029876098     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Coates A, Abraham S, Kaye SB, et al. On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203-8.
2. Cooper S, Georgiou V. The impact of cytotoxic chemotherapy - perspectives from patients, specialists and nurses. Eur J Cancer 1992;28A(suppl 1);S36-8.
3. Frytak S, Moertel CG. Management of nausea and vomiting in the cancer patient JAMA 1981;245:393-6.
4. Laszlo J, Lucas VS Jr. Emesis as a critical problem in chemotherapy. N Engl J Med 1981;305:948-9.
5. Fozard JR. MDL-72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn Schmiedebergs Arch Pharmacol 1984;326:36-44.
6. Miner WD, Sauger GJ. Inhibition of cisplatin induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 1986;88:497-9.
7. 3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 1991;42:551-68.
8. Milne RJ, Heel RC. Ondansetron Therapeutic use as an antiemetic. Drugs 1991;41:574-95.
9. Plosker GL, Goa KL. Granisetron. A review of its pharmacological properties and therapeutic use as an andemetic. Drugs 1991,42:805-24.
10. Lee CR, Plosker GL, McTavish D. Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 1993;46:925-43.
11. Markham. A, Sorkin EM. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 1993;45:931-52
12. 3 receptor antagonists the same? Eur J Cancer 1992;28A(suppl 1):S2-6
13. Dilly S. Are granisetron and Ondansetron equivalent in the clinic? Eur J Cancer 1992;28A(suppl 1):S32-5.
14. Clavel M, Soukop M, Greenstreet YLA. Improved control of emesis and quality of life with ondansetron in breast cancer Oncology 1993,50:180-5.
15. Beck TM. Efficacy of Ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials. Semin Oncol 1992;19(6 suppl 15):20-5.
16. Beck TM, Ciociola AA, Jones SE, et al. Efficacy of oral Ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 1993;118.407-13.
17. 3 antagonists incorporating a novel bridged pseudopelletierine ring system Act Chim Ther 1989,16:187-9
18. 3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells Eur J Pharmacol 1992;21:9-13
19. Galvan M, Gittos MW, Fatmi M. Dolasetron mesylate. Drugs Future 1993,18.506-9
20. 3 receptor antagonist [abstr] Br J Pharmacol 1992,107(suppl).449P.
21. 3 receptors Drug Dev Res 1993;28:87-93.
22. 3 receptor antagonists, ICS 205-930, MDL 72222, MDL 73147EF and MDL 72699 Neuropharmacology 1992,31:553-60
23. 3 receptor antagonist, on A9 and A10 dopamine neurons. Eur J Pharmacol 1989;163:115-18.
24. 3 antagonist, facilitates latent inhibition in the rat. Pharmacol Biochem Behav 1992;42:519-22.
25. Boxenbaum H, Gillespie T, Heck K, Hahne W. Human dolasetron pharmacokinetics. II Absorption and disposition following single-dose oral administration to normal male subjects. Biopharm Drug Dispos 1993;14:131-41.
26. Boxenbaum H, Gillespie T, Heck K, Hahne W. Human dolasetron pharmacokinetics. 1 Disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 1992;13:693-701.
27. Hunt TL, Cramer M, Shah A, Stewart W, Hahne WF, Benedict CR. A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. J Clin Pharmacol 1995;35:705-12.
28. Finn AL. Toxicity and side effects of ondansetron. Semin Oncol 1992;19(4 suppl 10):53-60.
29. Grunberg SM, Stevenson LL, Russell CA, McDermed JE. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1989;7:1137-41.
30. Cerenex Pharmaceuticals. Ondansetron hydrochloride (Zofran) package insert. Research Triangle Park, NC, 1993.
31. Blackwell CP, Harding SM. The clinical pharmacology of ondansetron. Eur J Cancer Clin Oncol 1989;25(suppl 1):S21-4.
32. Bryson JC. Clinical safety of ondansetron. Semin Oncol 1992;19(6 suppl 15):26-32.
33. Helmers JHJH. Oral ondansetron in the prevention of postoperative nausea and vomiting. Eur J Anaesthesiol 1992;9(suppl 6).49-54.
34. Zhou SH, Wong S, Rautaharju PM, Karnik N, Calhoun HP. Should the JT rather than the QT interval be used to detect prolongation of ventricular repolarization? J Electrocardiol 1993,25(suppl):131-6
35. 3 receptor antagonists, in anestheozed dogs. Drug Dev Res 1991;24:277-84.
36. Baltzer L, Kris MG, Hinkley L, et al. Reversible electrocardiographic interval prolongations following the specific serotonin antagonists ondansetron (OND) and dolasetron mesylate (DM): a possible drug class effect without sequelae? [abstr] Proc Am Soc Clin Oncol 1994,13:433.
37. Lifsey DS, Gralla RJ, Clark RA, Kline RC. Electrocardiographic changes with serotonin antagonist antiemetics: rate of occurrence and clinical relevance [abstr]. Proc Am Soc Clin Oncol 1993;12:463.
38. Addehnan M, Erlichman C, Fine S, Warr D, Murray C. Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting J Clin Oncol 1990,8:337-41.